The Pharma Letter3 天
Fragile X syndrome market to quadruple to $111.9 million in USA and Germany by 2030
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...
Study suggests new molecular strategy for treating fragile X syndrome
Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...
US and German FXS market forecast to grow by combined $83.2m from 2025 to 2030
A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...
GlobalData on MSN9 天
Spinogenix reports top line outcomes from trial of therapy for Fragile X syndrome
US-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating ...
来自MSN1 天
New approach shows promise for treating fragile X syndrome
Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...
GEN19 小时
Fragile X Phenotypes Reversed in Mice by Targeting NMDA Receptors
MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.
MIT Neuroscientists Discover a Tiny Brain Receptor That Could Transform Fragile X Treatment
MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...
来自MSN17 天
What exactly is fragile X syndrome?
Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...
Harmony Biosciences price target lowered to $42 from $52 at Mizuho
Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $42 from $52 and keeps an Outperform rating on the shares. The firm ...